W Saliba1, O Barnett-Griness2, M Elias3, G Rennert4. 1. Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Department of Internal Medicine C, Emek Medical Center, Afula, Israel. Electronic address: saliba_wa@clalit.org.il. 2. Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. 3. The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Department of Internal Medicine C, Emek Medical Center, Afula, Israel. 4. Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services; The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; Department of Epidemiology and Disease Prevention, Office of the Chief Physician, Clalit Health Services Headquarters, Tel Aviv, Israel.
Abstract
BACKGROUND: Diabetes is associated with an increased risk of stroke in patients with atrial fibrillation. Whether glycemic control, evaluated by glycated hemoglobin, affects the risk of stroke in diabetic patients with atrial fibrillation remains unknown. OBJECTIVE: To examine the association between glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation. METHODS: By using the computerized database of the largest health maintenance organization in Israel, we identified a cohort of adults (age ≥20 years) in whom atrial fibrillation was diagnosed before January 1, 2012. Eligible subjects had no previous stroke or transient ischemic attack and were not on anticoagulants at baseline. The cohort (37,358 subjects) was followed for the first episode stroke or transient ischemic attack up to December 31, 2012. RESULTS: A total of 1052 subjects had stroke during 35,278 person-years of follow-up (stroke rate 2.98 per 100 person-years). Cox proportional hazards regression analysis adjusting for CHA2DS2-VASc score risk factors revealed that compared with subjects without diabetes, the hazard ratio for stroke was 1.04 (95% confidence interval [CI] 0.83-1.30) for the lowest glycated hemoglobin quartile (<6.35%), 1.14 (95% CI 0.92-1.42) for the second quartile (6.35%-6.90%), 1.46 (95% CI 1.19-1.79) for the third quartile (>6.90%-7.70%), and 1.63 (95% CI 1.33-2.00) for the highest quartile(>7.70%) (for trend, P < .001). In diabetic patients (n = 11,176), the hazard ratio for stroke was 1.17 (95% CI 1.09-1.26) for every 1% increment in glycated hemoglobin level. The area under the receiver operating characteristic curve was 0.585 for the CHA2DS2-VASc score, which increased to 0.604 when glycated hemoglobin was included in the model (P = .038). CONCLUSION: Glycated hemoglobin is directly associated with stroke risk, and it improves the predictive accuracy for stroke in diabetic patients with atrial fibrillation.
BACKGROUND:Diabetes is associated with an increased risk of stroke in patients with atrial fibrillation. Whether glycemic control, evaluated by glycated hemoglobin, affects the risk of stroke in diabeticpatients with atrial fibrillation remains unknown. OBJECTIVE: To examine the association between glycated hemoglobin and risk of first episode stroke in diabeticpatients with atrial fibrillation. METHODS: By using the computerized database of the largest health maintenance organization in Israel, we identified a cohort of adults (age ≥20 years) in whom atrial fibrillation was diagnosed before January 1, 2012. Eligible subjects had no previous stroke or transient ischemic attack and were not on anticoagulants at baseline. The cohort (37,358 subjects) was followed for the first episode stroke or transient ischemic attack up to December 31, 2012. RESULTS: A total of 1052 subjects had stroke during 35,278 person-years of follow-up (stroke rate 2.98 per 100 person-years). Cox proportional hazards regression analysis adjusting for CHA2DS2-VASc score risk factors revealed that compared with subjects without diabetes, the hazard ratio for stroke was 1.04 (95% confidence interval [CI] 0.83-1.30) for the lowest glycated hemoglobin quartile (<6.35%), 1.14 (95% CI 0.92-1.42) for the second quartile (6.35%-6.90%), 1.46 (95% CI 1.19-1.79) for the third quartile (>6.90%-7.70%), and 1.63 (95% CI 1.33-2.00) for the highest quartile(>7.70%) (for trend, P < .001). In diabeticpatients (n = 11,176), the hazard ratio for stroke was 1.17 (95% CI 1.09-1.26) for every 1% increment in glycated hemoglobin level. The area under the receiver operating characteristic curve was 0.585 for the CHA2DS2-VASc score, which increased to 0.604 when glycated hemoglobin was included in the model (P = .038). CONCLUSION: Glycated hemoglobin is directly associated with stroke risk, and it improves the predictive accuracy for stroke in diabeticpatients with atrial fibrillation.
Authors: Sri Harsha Patlolla; Hon-Chi Lee; Peter A Noseworthy; Waldemar E Wysokinski; David O Hodge; Eddie L Greene; Bernard J Gersh; Rowlens M Melduni Journal: Am J Cardiol Date: 2020-06-30 Impact factor: 2.778
Authors: Husam Abdel-Qadir; Madison Gunn; Iliana C Lega; Andrea Pang; Peter C Austin; Sheldon M Singh; Cynthia A Jackevicius; Karen Tu; Paul Dorian; Douglas S Lee; Dennis T Ko Journal: J Am Heart Assoc Date: 2022-02-08 Impact factor: 6.106
Authors: Gene R Quinn; Olivia N Severdija; Yuchiao Chang; Liane O Dallalzadeh; Daniel E Singer Journal: J Am Heart Assoc Date: 2018-06-09 Impact factor: 5.501
Authors: Handrean Soran; Moulinath Banerjee; Jamal B Mohamad; Safwaan Adam; Jan Hoong Ho; Shakawan M Ismaeel; Shaishav Dhage; Akheel A Syed; Ibrahem M A Abdulla; Naveed Younis; Rayaz A Malik Journal: Biomed Res Int Date: 2018-03-12 Impact factor: 3.411
Authors: John Peter Mitsios; Elif Ilhan Ekinci; Gregory Peter Mitsios; Leonid Churilov; Vincent Thijs Journal: J Am Heart Assoc Date: 2018-05-17 Impact factor: 5.501
Authors: Francis E Ugowe; Anne S Hellkamp; Allen Wang; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Manesh R Patel; Jonathan P Piccini Journal: Heart Rhythm O2 Date: 2021-04-20